Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,935 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT01635283 | Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma | completed | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04588987 | Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT04552977 | A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma | unknown | Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04547621 | HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM(HSCK-010) | unknown | Phase 1 / Phase 2 | 50 | Huashan HospitalOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04547855 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | unknown | Phase 2 | 54 | Yonggao MouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01567202 | Study of DC Vaccination Against Glioblastoma | unknown | Phase 2 | 100 | Huashan HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01390948 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 14 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00179920 | Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma | completed | Phase 2 | 30 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02540161 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 43 | Annick DesjardinsOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00823459 | Everolimus in Treating Patients With Recurrent Low-Grade Glioma | completed | Phase 2 | 58 | Susan ChangOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03252171 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04406610 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 0 | Jul 16, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT04450160 | Trial of AEO in New Glioblastoma (GBM)(AEO) | unknown | Phase 2 | 80 | MetVital, Inc.INDUSTRY | 0 | Jun 29, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04388033 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | unknown | Phase 1 / Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT00795665 | Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma | completed | Phase 2 | 7 | University of California, DavisOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01140568 | Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | completed | Phase 2 | 38 | David Piccioni, M.D., Ph.DOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma(ALECSAT) | completed | Phase 2 | 62 | CytoVac A/SINDUSTRY | 1 | Apr 30, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02342379 | TH-302 in Combination With Bevacizumab for Glioblastoma | completed | Phase 2 | 35 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | terminated | Phase 1 / Phase 2 | 3 | Eben RosenthalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04316039 | Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | recruiting | Phase 2 / Phase 3 | 250 | West China HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01067469 | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02715297 | Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma(GlioCave/NOA17) | unknown | Phase 2 | 162 | Technical University of MunichOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | terminated | Phase 2 | 38 | Daiichi SankyoINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01967810 | ANG1005 in Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 73 | Angiochem IncINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01402063 | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation | completed | Phase 2 | 63 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | Darell BignerOTHER | 0 | Feb 11, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT01158651 | Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas(NFC-RAD001) | completed | Phase 2 | 23 | University of Alabama at BirminghamOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04224441 | Repurposing Chlorpromazine in the Treatment of Glioblastoma(RACTAC) | unknown | Phase 2 | 41 | Marco G Paggi, MD, PhDOTHER | 1 | Jan 13, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 5, 2020source: clinicaltrials